We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

78 hedge funds and large institutions have $116M invested in Inovio Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 9

130% more capital invested

Capital invested by funds: $50.6M → $116M (+$65.6M)

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

44% more funds holding

Funds holding: 5478 (+24)

28% more call options, than puts

Call options by funds: $660K | Put options by funds: $516K

0.13% more ownership

Funds ownership: 0.17%0.3% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
78
Holders Change
+24
Holders Change %
+44.44%
% of All Funds
2.25%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
33
Increased
21
Reduced
12
Closed
9
Calls
$660K
Puts
$516K
Net Calls
+$144K
Net Calls Change
+$144K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$18.9M +$4.94M +34,411 +41%
State Street
2
State Street
Massachusetts
$17.1M -$7.08M -49,327 -32%
TA
3
Teachers Advisors
New York
$15.5M +$13.9M +97,005 New
O
4
OrbiMed
New York
$13.3M +$11.9M +83,063 New
TCIM
5
TIAA CREF Investment Management
New York
$9.21M +$8.27M +57,619 New
Morgan Stanley
6
Morgan Stanley
New York
$6.11M +$2.86M +19,955 +109%
BC
7
Broadfin Capital
New York
$4.16M +$3.74M +26,042 New
Jennison Associates
8
Jennison Associates
New York
$4.16M +$3.74M +26,042 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.97M +$254K +1,771 +11%
EA
10
Emerald Advisers
Pennsylvania
$2.44M +$2.19M +15,275 New
Jane Street
11
Jane Street
New York
$1.49M +$1.19M +8,297 +829%
U
12
UBS
Switzerland
$1.41M +$1.25M +8,740 +13,656%
KCM
13
Knoll Capital Management
Florida
$1.36M
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$1.31M +$1.11M +7,753 +1,685%
Northern Trust
15
Northern Trust
Illinois
$1.3M +$91K +634 +8%
CS
16
Credit Suisse
Switzerland
$1.22M +$864K +6,018 +368%
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$1.22M +$1.1M +7,642 New
BIT
18
BlackRock Institutional Trust
California
$1.09M +$478K +3,333 +95%
Citigroup
19
Citigroup
New York
$1.06M -$95.3K -664 -9%
EI
20
EAM Investors
California
$1.01M +$908K +6,323 New
AQR Capital Management
21
AQR Capital Management
Connecticut
$931K +$422K +2,940 +102%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$803K +$61.1K +426 +9%
BG
23
BlackRock Group
United Kingdom
$686K +$616K +4,294 New
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$685K
Goldman Sachs
25
Goldman Sachs
New York
$673K -$2.5M -17,443 -81%

INO Hedge Fund Activity: Q1 2014 in Review

78 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2014, worth a combined $116M — up 130% from $50.6M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new INO positions and 9 closed out — a net gain of 24 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was Teachers Advisors, opening a new position worth an estimated $13.9M. The largest seller was State Street, cutting an estimated $7.08M.

  • 78 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2014, up from 54 in Q4 2013.
  • Funds reported $116M of Inovio Pharmaceuticals stock for Q1 2014, up 130% quarter-over-quarter.
  • 33 funds opened new Inovio Pharmaceuticals positions in Q1 2014 and 9 closed out, a net change of +24 holders.
  • The largest Inovio Pharmaceuticals buyer in Q1 2014 was Teachers Advisors, an estimated $13.9M added.
  • The largest Inovio Pharmaceuticals seller in Q1 2014 was State Street, an estimated $7.08M sold.

Based on aggregated 13F filings for Q1 2014.